Also AMERICAN Regent has been given rights for entire operations of of injectafer in USA. I am not sure what arrangements CSL have with them, but I won’t expect much more than royalty type of income out of this from USA. However the EPS forecast of 12.50+ for 2025 still stands considering plasma volume and margin increases, availability of plasma, Vifor integration benefits, A$ Weakness. This results will be good CAGR rate and carry high PE multiple as CSL usually do.
CSL Price at posting:
$308.14 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)